Australia's most trusted
source of pharma news
Friday, 27 February 2026
Posted 27 February 2026 AM
Already fending off biosimilar competition for its blockbuster eye drug Eylea, Bayer could soon face a competitor that has shown superiority in wet age-related macular degeneration (AMD).
Ocular Therapeutix compared Axpaxli, a hydrogel version of Pfizer’s kidney cancer med Inlyta, to low-dose Eylea in its Phase 3 SOL-1 study, finding that the drug met its primary endpoint of superiority at week 36 with “high statistical significance,” according to the company.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.